All In Biotech

NDA 019531 · B Braun

Nutrilipid 10%

Soybean Oil · Injection · Lipid Emulsion

Last checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

May 28, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

146

39 Phase 3, 4 recruiting

FAERS reports

680

356 serious, 67 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2026.

Nutrilipid ® 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated. Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Nutrilipid 20% administered intravenously provides biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression. Nutrilipid 20% causes an increase in heat production, decrease in respiratory quotient, and increase in oxygen consumption following its...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • NUTRILIPID 10% · SOYBEAN OIL 10% · INJECTABLE, INJECTION · Discontinued
  • NUTRILIPID 20% · SOYBEAN OIL 20% · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Soybean Oil" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chills134
  • pyrexia133
  • nausea83
  • vomiting54
  • chest discomfort45
  • dyspnoea44
  • palpitations34
  • abdominal distension31
  • rash29
  • dizziness28
  • pruritus27
  • abdominal pain23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20082
20091
20103
20111
20124
20141
20159
201643
201748
201887
2019147
202081
202123
202248
202373
202459
202532
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 342 on PubMed

Sponsor: B Braun · Also marketed as Nutrilipid 20%

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.